TheFly.com
SLRX
Salarius Pharmaceuticals
$
()
Salarius announces additional cost saving measures, CEO transitions to part-time
Salarius issued U.S. patent for next-gen targeted protein degraders
Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment
Salarius Pharmaceuticals completes FDA Type B meetng for seclidemstat
Salarius Pharmaceuticals downgraded with programs halted at Ladenburg
Salarius Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
Salarius Pharmaceuticals explores strategic alternatives, begins cost savings
Salarius Pharmaceuticals reports Q2 EPS ($1.43), consensus ($1.30)
Salarius Pharmaceuticals trading resumes
Salarius Pharmaceuticals trading halted, news pending
Salarius receives FDA clearance for IND application of SP-3164 Phase 1 trial
Salarius presents SP-3164 targeted protein degrader preclinical data
Salarius Pharmaceuticals files ot sell 11.16M shares of common stock for holders
Copyright ©1998-2024 Thefly.com LLC
